Tagged with CCE

Belgium Diane Kleinermans leads the reimbursement commission at Belgium’s medicines payer, the National Institute for Health and Disability Insurance (NIHDI). With Belgium currently undergoing a landmark reform of its reimbursement procedure, Kleinermans discusses the access picture in the country today, international HTA collaborations, and the delicate balance between maintaining the stability…

UAE Zeina Sfeir Lahoud of Biologix, a Dubai-based firm that represents international pharma companies by bringing innovative drugs to market in the Middle East and North Africa (MENA) region, highlights important recent developments for the company – including a groundbreaking “value management agreement” in the UAE – and her hopes for…

Belgium Speaking exclusively to PharmaBoardroom, Pedro Facon outlines the scope and aims of the new medicines roadmap that NIHDI has recently presented to the Belgian Ministry of Health following extensive stakeholder discussions in 2022. In a wide-ranging and in-depth conversation, Facon describes his hopes for tackling the growing number and length…

Belgium An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She highlights some of her key priorities and explains Belgium’s strategic importance for Pfizer – a country where it has its…

Greece Greek medtech industry veteran Dimitris Nikas outlines what makes him optimistic about the future of Greek healthcare, highlights the areas for systemic improvement and how EU recovery funding could help, and explains Greece’s relevance to Medtronic as an increasingly open early launch market for some of its most innovative new…

LatAm A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences investment destination. LatAm has a robust heritage of scientific achievement – Bernardo Houssay (1947) and César Milstein (1984) of Argentina…

Greece Angelini Pharma’s Gabriele Jannis draws on his experience in both Russia and Romania to highlight some of the key challenges for European mid-caps like Angelini in Greece, the importance of CEE countries in the company’s internationalisation efforts, and his hopes for future reform that increases the level of certainty in…

Belgium Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on top of the rapidly evolving technologies being brought forward today, and the significance of a new early access programme for…

Greece Managing Director of MSD Greece, Cyprus & Malta Agata Jakoncic, who also serves as president of Greece’s PhRMA Innovation Forum (PIF), draws on her three decades of industry experience to outline some of the key challenges in the Greek pharma market today which threaten its sustainability and the ability of…

Greece Yvoni Papastelatou outlines Sanofi’s commitment to Greece, where the multinational firm has a strong and diverse team, a burgeoning clinical trial footprint, and is rolling out the global ‘play to win’ strategy, with a common ambition to leverage science and innovation. She also touches on the access challenges in the…

Belgium pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played in Belgium’s COVID-19 response and recognition of the role that innovative pharma plays in Belgium. Ven also outlines the persistent…

Belgium One year into his first country management assignment at Takeda Belgium, Michael Nesrallah reflects on his initial impressions of the Belgian pharma market as well as its similarities and differences with that of his native US. Belgium plays host to Takeda’s third-largest manufacturing site globally – a carbon neutral facility…